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OBJECTIVES We examined the association of baseline plasma fibrinogen with future risk of myocardial
infarction (MI) in the Physicians’ Health Study.
BACKGROUND Elevated plasma fibrinogen increases and low dose aspirin decreases risk of MI. However,
prospective data are limited about their interrelationships.
METHODS Blood samples were prospectively collected at baseline from 14,916 men in the Physicians’
Health Study, aged 40 to 84 years, who were randomly assigned to take aspirin (325 mg every
other day) or placebo for 5 years. We measured baseline plasma fibrinogen among 199
incident cases of MI and 199 age- and smoking-matched control subjects free of cardiovas-
cular disease at the time of the case’s diagnosis.
RESULTS Cases had significantly higher baseline fibrinogen levels (geometric mean: 262 mg/dl) than
did control subjects (245 mg/dl, p 5 0.02). Those with high fibrinogen levels ($343 mg/dl,
the 90th percentile distribution of the control subjects) had a twofold increase in MI risk (age-
and smoking-adjusted relative risk 5 2.09, 95% confidence interval 5 1.15 to 3.78) compared
with those with fibrinogen below 343 mg/dl. Adjustment for lipids and other coronary risk
factors as well as randomized aspirin assignment did not materially change the result.
Furthermore, we observed no interaction between fibrinogen level and aspirin treatment.
CONCLUSIONS Among these apparently healthy U.S. male physicians, fibrinogen is associated with increased
risk of future MI independent of other coronary risk factors, atherogenic factors such as lipids
and antithrombotics such as aspirin. (J Am Coll Cardiol 1999;33:1347–52) © 1999 by the
American College of Cardiology
Fibrinogen, an acute phase protein and a clotting factor,
appears to be an independent risk factor for cardiovascular
disease (1), but the mechanism(s) are still uncertain. As a
key determinant of plasma and red cell viscosity, elevated
levels of fibrinogen may decrease blood flow, particularly
through stenotic vessels (2). Through conversion to fibrin,
fibrinogen may promote thrombus formation. Fibrinogen
appears to directly enhance atherogenesis by its conversion
to fibrin, which binds low density lipoprotein and stimulates
proliferation of vascular smooth muscle (3–5). In addition,
fibrinogen may bind to platelet membrane glycoprotein
IIb/IIIa (fibrinogen receptor), which in turn is a precondi-
tion for platelet aggregation in vivo (6). Also, platelets have
been proposed as a link between fibrinogen levels and the
development of cardiovascular disease, both during the early
stages of vascular lesion development and subsequently as
platelet aggregation on occluding thrombus. The North-
wick Park Heart Study found that platelet aggregatability
(defined as the median effective dose for aggregation by
adenosine diphosphate) significantly correlated with plasma
fibrinogen in men even within its normal physiologic range
(7,8).
Fibrinogen has been extensively investigated in epidemi-
ologic studies, and some pharmacologic approaches, includ-
ing aspirin, bezafibrate, pentoxyfyline and ticlopidine ad-
ministration, have been suggested to counteract some of the
pathologic effects of elevated fibrinogen, including increased
viscosity, platelet aggregation and red blood cell rigidity
(9–12). However, no randomized trial data have been
available to demonstrate whether such measures have appli-
cations for primary prevention of cardiovascular disease.
The Physicians’ Health Study, a randomized, double-
blind, placebo-controlled trial of low dose aspirin among
healthy male physicians, showed a 44% reduction in the risk
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of first myocardial infarction (MI) in the aspirin group (13).
In the present study, using a nested case–control design, we
sought to examine the association of plasma fibrinogen with
future risk of MI among these apparently, healthy middle-
aged U.S. male physicians. This aspirin trial also provides us
a unique opportunity to examine the primary preventive
effect of aspirin on the relation between fibrinogen and the
incidence of MI.
METHODS
Population and specimen collection. The subjects and
methods of the Physicians’ Health Study are described in
detail elsewhere (13). Briefly, this was a randomized,
double-blind, placebo-controlled 2 3 2 factorial trial of low
dose aspirin (Bufferin, Bristol-Myers Products, 325 mg
every other day) and beta-carotene (Lurotin, BASF, 50 mg
on alternate days) (13). A total of 22,071 U.S. male
physicians, aged 40 to 84 years in 1982, were enrolled. Men
were excluded if they had a prior history of myocardial
infarction, stroke or transient ischemic attack, cancer (ex-
cept nonmelanoma skin cancer), current renal or liver
disease, peptic ulcer or gout, contraindication to aspirin or
current use of aspirin, other platelet active agents or vitamin
A supplements. The aspirin component of the trial was
terminated on January 25, 1988, principally because of a
44% reduction in the incidence of first myocardial infarction
among the aspirin group.
Between August 1982 and December 1984, during the
run-in period when all men were taking aspirin, we sent kits
for blood sampling to participants who were instructed to
have their blood drawn into ethylenediaminetetraacetic acid
(EDTA) vacutainer tubes, to centrifuge them and to return
the plasma in the polypropylene cryopreservation vials by
prepaid overnight courier. The kit included a cold pack to
keep the specimens cool (but not frozen) until receipt at
Channing Laboratory the following morning, when they
were aliquoted and stored at 280°C. During storage, no
specimen thawed or warmed substantially. We received
specimens from 14,916 (68%) of the randomized physicians,
over 70% between September and November 1982.
Ascertainment and confirmation of end points. Cases of
nonfatal myocardial infarction were reported on question-
naires mailed to participants every six months. Deaths were
usually reported by the families or postal authorities. Per-
sistent nonresponders to the questionnaires were tele-
phoned. Follow up for nonfatal events was 99.7% complete,
and for fatal outcomes, 100%. Medical records were re-
viewed by the End Points Committee without knowledge of
treatment assignment. All cases of myocardial infarction
included in this analysis met the World Health Organiza-
tion criteria (14), which require symptoms plus either
enzyme elevations or diagnostic electrocardiographic
changes. For fatal cases, we also accepted diagnoses based
on autopsy, or confirmation by records that the death was
due to coronary heart disease (International Classification of
Diseases codes 411–414). Silent infarcts discovered on
routine examination were not included, because they could
not be assigned an accurate date. Sudden deaths in individ-
uals with no history of coronary disease were not included,
because coronary disease could not be confirmed as the
cause of death.
Selection of control subjects. Each case was matched to
one control subject free from MI at the time of the case’s
diagnosis. Control subjects were randomly selected from
participants who met the matching criteria of age (61 year),
smoking habit (current, past or never smoker) and time
from randomization in six-month intervals. Aliquots from
cases and control subjects were paired, with the positions
varied at random within the pairs. The pairs were handled
together and identically throughout processing and analysis.
Laboratory analyses. After five years of follow up, samples
from 204 men who subsequently developed myocardial
infarction were analyzed for fibrinogen levels together with
matched control samples. The paired, blinded plasma sam-
ples were shipped on dry ice to the Department of Labo-
ratory Medicine, University of Washington for analyses.
Fibrinogen in plasma was measured with a polymerization
method as originally described by Clauss (15). Blind paired
quality-control samples (n 5 10 pairs) were interspersed at
random among the specimens. The quality-control samples
were aliquots of a large, well mixed plasma pool from
healthy volunteers that were treated identically to the
samples collected from the participants. The mean within-
pair coefficient of variation for plasma fibrinogen levels in
these paired quality-control specimens was 17%. We also
measured plasma levels of total and high density lipoprotein
(HDL) cholesterol (16).
We compared fibrinogen levels in split samples of plasma
collected with EDTA or sodium citrate vacuum tubes
among nine young volunteers. Plasma treated with EDTA
had lower fibrinogen levels (mean 6 SD: 219 6 55 mg/dl)
than citrated plasma (232 6 68 mg/dl), but the levels of the
two treatments were highly correlated (r 5 0.95, p , 0.01).
Statistical analysis. From 204 paired cases and control
subjects, we excluded five with missing data for other
coronary risk factors. Because of the skewed distribution of
fibrinogen levels, we used natural log transformed fibrino-
gen for the paired t test. We used conditional logistic
regression methods for the main effect analyses. To estimate
Abbreviations and Acronyms
EDTA 5 ethylenediaminetetraacetic acid
MI 5 myocardial infarction
RR 5 relative risk
TC/HDL 5 total to high density lipoprotein cholesterol
ratio
95% CI 5 95% confidence interval
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whether there was a linear association between fibrinogen
levels and risk of myocardial infarction, we defined quintile
and decile cut points based on the distribution among
control subjects and examined the age- and smoking-
adjusted relative risk (RR) (estimated by the odds ratios)
using the lowest quintile or decile as the reference group.
We then defined fibrinogen levels $343 mg/dl (the 90th
percentile among the control subjects) as abnormally high
values, those below this level as normal. Unconditional
logistic regression models were used for testing of interac-
tions adjusting for the matching variables and for further
simultaneous adjustment for other coronary risk factors.
Interactions were assessed using the product of both expo-
sures as continuous variables in the model. We also used
dichotomized variables to assess interaction by comparing
the log likelihood statistics of the main effect model with the
joint effect model. To estimate the joint effect of aspirin and
fibrinogen on the risk of myocardial infarction, four groups
were formed based on the cross classification by the two
fibrinogen levels (normal and high) and aspirin or placebo
assignment. We then calculated the RR comparing each
group with the reference group of men with normal fibrin-
ogen levels and aspirin assignment. Because aspirin use
modifies the association of total to HDL cholesterol (TC/
HDL) ratio with MI risk (the protective effect of aspirin is
more pronounced among those with a low TC/HDL ratio)
(16), and to avoid three-way interaction, we estimated the
joint effect of fibrinogen and TC/HDL ratio only among
those who were assigned to placebo. We defined the highest
tertile of TC/HDL as high ratio and the two lower tertiles
of TC/HDL ratio (to avoid very small numbers in some of
the subgroups) as normal and formed four groups by
cross-classifying the two categories of fibrinogen and TC/
HDL ratio. All p values are two tailed, and statistical
significance is based on the 0.05 level. The analyses were
done using SAS (17).
RESULTS
Among these apparently healthy U.S. physicians, men who
subsequently developed MI had higher baseline plasma
fibrinogen levels, and a larger proportion of them had
fibrinogen values above the 90th percentile of the distribu-
tion among control subjects (Table 1). Age and smoking
were matching variables and hence distributed identically
between cases and control subjects. As expected, cases had a
higher mean body mass index, lower HDL cholesterol,
higher, TC/HDL ratio and greater prevalence of angina,
diabetes and hypertension (Table 1). Table 2 shows the
Spearman correlation coefficients between fibrinogen and
these risk factors according to case or control status. Among
control subjects, fibrinogen was slightly but significantly
correlated with age, HDL cholesterol, TC/HDL ratio,
cigarette smoking and history of hypertension (Table 2).
We did not observe any significant seasonal variations of
fibrinogen levels.
We assessed the association of plasma fibrinogen levels
and risk of future MI based on the quintile distribution of
the control group and observed a nonsignificant and non-
linear positive association. The RRs (95% confidence inter-
val [95% CI]) for the second to the fifth quintiles compared
with the lowest were: 1.08 (0.59 to 1.99), 0.95 (0.50 to
1.83), 1.27 (0.65 to 2.47) and 1.50 (0.77 to 2.90) controlling
for age and smoking status. However, when fibrinogen
levels were further divided into deciles, we observed a
significant increased risk of MI only among those in the
Table 1. Characteristics of 199 Men With Myocardial Infarction (Case Subjects) and 199 Matched Control Subjects in the
Physicians’ Health Study
Risk Factor
Case
Subjects
Control
Subjects p Value
Fibrinogen (mg/dl)* 262 245 0.02
Fibrinogen $343 mg/dl† (%) 19 (n 5 37) 10 (n 5 20) 0.02
Age (yr) 60.3 6 8.5 60.3 6 8.5 Matching factor
Quetelet index (wt[kg]ht[m]2) 25.6 6 3.2 24.8 6 2.7 0.003
Total cholesterol (mg/dl) 218 6 38 213 6 34 0.26
HDL cholesterol (mg/dl) 44 6 11 49 6 12 0.0001
TC/HDL (ratio) 5.3 6 1.5 4.6 6 1.2 0.0001
Alcohol consumption (drinks/day) 0.48 6 0.44 0.54 6 0.46 0.18
Cigarette smoking (%)
Never 37 37 Matching factor
Past 47 47 Matching factor
Current 16 16 Matching factor
History of diabetes (%) 8 4 0.08
History of angina (%) 6 2 0.03
History of hypertension (%) 32 20 0.006
Aspirin assignment (%) 32 46 0.005
*Geometric means, p value based on nature log-transformed values. †The 90th percentile of the control distribution. TC/HDL 5 total to high density lipoprotein cholesterol
ratio.
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90th percentile (RR 5 2.34, 95% CI 5 1.17 to 4.67
compared with the lower 50th percentile, Fig. 1). We then
combined all those up to the 90th percentile (normal level,
,343 mg/dl) as the reference group, and those in the
highest decile of fibrinogen as high level ($343 mg/dl). We
observed an approximate twofold increase in risk of MI
among those with high fibrinogen levels compared with
those with normal levels (RR 5 2.09, 95% CI 5 1.15 to
3.78). Adding aspirin assignment (using placebo as the
reference group) into the model did not change the results
for fibrinogen (RR 5 2.09, 95% CI 5 1.15 to 3.78); men
assigned to aspirin had a 45% reduction in risk (RR 5 0.55,
95% CI 5 0.36 to 0.84). Further adjustment for other
coronary risk factors (including the ratio of total to HDL
cholesterol, alcohol consumption, body mass index, homo-
cysteine levels and history of diabetes, hypertension and
angina) had no effect on this relationship (RR 5 2.02, 95%
CI 5 1.06 to 3.84). Stratified analyses by years of follow-up
(the first two years and the third to fifth year) did not
materially alter the results.
Because this study is nested in the randomized aspirin
trial, we assessed whether the association of baseline fibrin-
ogen level with the risk of MI was different among those
assigned to aspirin or placebo. We conducted a stratified
analysis according to normal and high fibrinogen level and
aspirin and placebo assignment. In both treatment groups,
men with high fibrinogen levels had twice the risk of those
with normal levels (,343 mg/dl). Men with high fibrinogen
levels and in the placebo group had 3.6-fold higher risk
(RR 5 3.62, 95% CI 5 1.57 to 8.36) compared with those
with normal fibrinogen who were on aspirin (Fig. 2).
Conversely, aspirin treatment reduced MI risk from 32%
among men with high fibrinogen levels to 45% among those
with normal levels. There was no significant interaction
between aspirin assignment and fibrinogen level (pinteraction
5 0.46).
Assmann et al. (18) and Thompson et al. (19) proposed
that the effect of fibrinogen varied according to the athero-
genic lipid profile. We assessed the joint effect of elevated
fibrinogen level and TC/HDL ratio on the risk of myocar-
dial infarction adjusted for age and smoking status among
those who were assigned to placebo (134 cases and 109
control subjects). We excluded those assigned to aspirin,
because aspirin treatment interacts with the TC/HDL ratio;
aspirin was less protective among those with TC/HDL
ratios in the higher two quintiles (16). We reported the
TC/HDL ratio results because it was a better predictor of
future risk of MI than TC and HDL assessed separately
(16). In contrast to the two previous studies (18,19), we
found no significant interaction between fibrinogen and
TC/HDL ratio using either continuous variables or dichot-
omized variables (pinteraction 5 0.48). Compared with men
Table 2. Spearman Correlation Coefficients Between Fibrinogen
Levels and Coronary Risk Factors Among 199 Men With
Myocardial Infarction (Case Subjects) and 199 Matched Control
Subjects in the Physicians’ Health Study
Risk Factor
Case
Subjects
Control
Subjects Total
Age 0.15* 0.19† 0.17†
Quetelet index 0.02 0.08 0.06
Total cholesterol 0.03 0.13 0.09
HDL cholesterol 0.003 20.15* 20.08
TC/HDL 0.03 0.25† 0.15†
Alcohol consumption
(drinks/day)
(n 5 198 pairs)
20.09 20.02 20.06
Cigarette smoking 0.06 0.17* 0.12*
History of diabetes 0.01 0.05 0.03
History of angina 20.13 20.08 20.10
History of hypertension 0.02 0.16* 0.09
Aspirin assignment 0.12 20.01 0.05
*p , 0.05. †p , 0.01.
TC/HDL 5 total to high density lipoprotein cholesterol ratio.
Figure 1. Age- and smoking-adjusted relative risk (95% confi-
dence interval) of future myocardial infarction associated with
baseline plasma fibrinogen levels in the Physicians’ Health Study.
Numbers of cases/control subjects were: 89/99 in the 1st to 50th
percentile, 73/80 in the 51st to 90th percentile and 37/20 in the
.90th percentile.
Figure 2. Age- and smoking-adjusted relative risk (95% confi-
dence interval) of future myocardial infarction according to fibrin-
ogen levels and aspirin assignment in the Physicians’ Health Study.
Numbers of cases/control subjects were: in aspirin group, 50/80 for
fibrinogen ,343 mg/dl, 15/10 for fibrinogen $343 mg/dl; in
placebo group, 112/99 for fibrinogen ,343 mg/dl, 22/10 for
fibrinogen $343 mg/dl.
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with normal fibrinogen and in the low and medium tertiles
of TC/HDL (52 cases and 66 control subjects), the RRs
were 2.67 (95% CI 5 0.84 to 8.48) for those with high
fibrinogen and in the low and medium tertiles of TC/HDL
ratio (10 cases and five control subjects). Among men in the
highest tertile of TC/HDL ratio, the RRs were: 2.39 (95%
CI 5 1.35 to 4.22) for those with normal fibrinogen (60
cases and 33 control subjects) and 3.59 (95% CI 5 1.13 to
11.40) for those with high fibrinogen levels (12 cases and
five control subjects). Further adjustment of other coronary
risk factors did not materially change the results. This
finding suggests that the effect of fibrinogen is not substan-
tially modified by lipid levels.
DISCUSSION
Plasma fibrinogen levels predict MI risk. In these appar-
ently healthy U.S. male physicians, those who developed
myocardial infarction within five years had significantly
higher baseline fibrinogen levels than their age- and
smoking-matched control subjects. This association seems
to be nonlinear after controlling for age and cigarette
smoking. The increased risk was most evident among men
with abnormally high fibrinogen level (above the 90th
percentile, 343 mg/dl), who had an approximately, twofold
increase in risk compared with those with plasma fibrinogen
levels below 343 mg/dl. There was no evidence of interac-
tion by aspirin use or atherogenic lipid profile.
The prospective design of the Physicians’ Health Study
minimized the possibility that this association can be
explained as an effect of selection bias. The average fibrin-
ogen levels were lower and the within-pair coefficient of
variation of the measurement was higher (17%) in our study
than those reported in other studies (20–25). It is likely that
the EDTA tubes we used for collecting blood samples may
cause low fibrinogen concentrations and high measurement
variation. However, the Caerphilly and Speedwell Studies
(20) also collected their blood samples in EDTA tubes, and
the men in these studies had higher fibrinogen levels (409
mg/dl and 366 mg/dl for men with ischemic heart disease
and disease-free men, respectively) than the men in our
study. Another possibility is that the male physicians in our
study had generally low coronary risk profiles, thus their
fibrinogen levels would be lower than those of the other
study populations. Lee et al. (25) found that individuals in
the highest socioeconomic class tended to have lower
fibrinogen levels, even after adjusting for smoking status.
Nevertheless, because the samples from cases and control
subjects were stored for the same duration and were handled
together and identically throughout processing, it is unlikely
that the methods of blood sample collection and storage or
measurement would cause any biases. Any random errors in
sample processing or measurement, or random within-
person day-to-day variability would attenuate the differ-
ences, yielding an underestimate of the apparent effect.
Our findings from the Physicians’ Health Study further
support the conclusion from other prospective studies that
fibrinogen is a strong and independent predictor for isch-
emic heart disease (1,20–27). This was true even after
controlling for other conventional coronary risk factors
including TC/HDL ratio and aspirin use. We observed no
material change in the risk between the first two years of
follow-up and the third to fifth year follow-up, which is
consistent with the findings that elevated fibrinogen levels
may also relate to preclinical nonsymptomatic atherosclero-
sis (5). Although we observed a weaker and nonlinear
association compared with most of the reported studies,
some showed a threshold effect of fibrinogen similar to that
which we observed (20,23). Another likely explanation may
stem from our presentation of age- and smoking-adjusted
RR, which would be lower than the univariate results
reported in most studies. Smoking represents the strongest
known environmental influence on fibrinogen levels (1), and
a dose-dependent increase in fibrinogen with smoking has
been confirmed (28). Part of the effect of cigarette smoking
on risk of ischemic heart disease is probably mediated
through its effect of raising fibrinogen (9,20). One study
showed that adjusting for smoking and preexistent ischemic
heart disease decreased the RR by 40% compared with an
analysis adjusted for age alone (20).
No effect modification by aspirin or lipids. The random-
ized, double-blind, placebo-controlled design of the study
provides unique evidence on the primary preventive efficacy
of aspirin on the risk of future MI by level of plasma
fibrinogen. Although small numbers in some of the sub-
group analyses limit the power to detect statistically, signif-
icant interactions, we observed no apparent interaction
between plasma fibrinogen levels and aspirin treatment.
Elevated fibrinogen levels were associated with about 2–2.5-
fold increased risk of MI regardless of aspirin treatment, and
aspirin treatment was associated with 32% to 45% reduction
in risk across all fibrinogen levels. We previously reported
that, among these healthy U.S. physicians, the TC/HDL
was a powerful predictor of myocardial infarction and that
the protective effect of aspirin was significantly more pro-
nounced among those with a lower TC/HDL ratio (16). In
the present study, among men assigned to placebo, we
observed no interaction between fibrinogen and TC/HDL
ratio; both elevated fibrinogen levels and high TC/HDL
ratio were independently associated with increased risk. In
contrast, the PROCAM study, a prospective study of
healthy men with an eight-year follow up, found that
elevated fibrinogen levels were associated with risk only
among men whose LDL cholesterol was in the higher two
tertiles, but not in the lowest (18). The ECAT study found
that elevated fibrinogen levels were associated with in-
creased risk of MI even at the lowest tertile of total
cholesterol among angina patients (19). However, unlike
our study, the ECAT study found that increased total
cholesterol levels were not associated with increased risk
among those with low fibrinogen levels (19). Taken to-
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gether, the totality of evidence suggests these are indepen-
dent noninteractive risk factors.
Summary. In summary, our prospective data from appar-
ently healthy U.S. physicians are consistent with previous
findings that plasma fibrinogen is associated with risk of
coronary heart disease, independent of other risk factors
including total to HDL cholesterol ratio and aspirin treat-
ment. Our results suggest that aspirin can reduce the risk of
MI by 32% to 45% through the whole range of fibrinogen
levels.
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